ATE231519T1 - Dinukleotide zur verwendung in der behandlung von lungenkrankheiten - Google Patents

Dinukleotide zur verwendung in der behandlung von lungenkrankheiten

Info

Publication number
ATE231519T1
ATE231519T1 AT96919139T AT96919139T ATE231519T1 AT E231519 T1 ATE231519 T1 AT E231519T1 AT 96919139 T AT96919139 T AT 96919139T AT 96919139 T AT96919139 T AT 96919139T AT E231519 T1 ATE231519 T1 AT E231519T1
Authority
AT
Austria
Prior art keywords
treatment
dinucleotides
lung diseases
lungs
subject
Prior art date
Application number
AT96919139T
Other languages
English (en)
Inventor
Monroe J Stutts Iii
Richard C Boucher Jr
Eduardo R Lazarowski
Cara A Geary
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE231519T1 publication Critical patent/ATE231519T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96919139T 1995-06-07 1996-06-06 Dinukleotide zur verwendung in der behandlung von lungenkrankheiten ATE231519T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,988 US5635160A (en) 1995-06-07 1995-06-07 Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
PCT/US1996/009190 WO1996040059A1 (en) 1995-06-07 1996-06-06 Dinucleotides useful for the treatment of lung disease

Publications (1)

Publication Number Publication Date
ATE231519T1 true ATE231519T1 (de) 2003-02-15

Family

ID=23933941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919139T ATE231519T1 (de) 1995-06-07 1996-06-06 Dinukleotide zur verwendung in der behandlung von lungenkrankheiten

Country Status (14)

Country Link
US (4) US5635160A (de)
EP (1) EP0831777B1 (de)
JP (1) JPH11506790A (de)
KR (1) KR100414699B1 (de)
CN (2) CN1086940C (de)
AT (1) ATE231519T1 (de)
AU (1) AU696845B2 (de)
BR (1) BR9609063A (de)
CA (1) CA2223894C (de)
DE (1) DE69625906T2 (de)
ES (1) ES2189874T3 (de)
MX (1) MX9709637A (de)
NO (1) NO975632L (de)
WO (1) WO1996040059A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
AU716486B2 (en) * 1995-04-13 2000-02-24 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
NZ332426A (en) * 1996-03-27 2000-09-29 Univ North Carolina Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US20020052309A1 (en) 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
DK0981534T3 (da) * 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
GB9711848D0 (en) * 1997-06-06 1997-08-06 William Harvey Research Limite Treatment and prophylaxis of infraction
WO1999003480A1 (en) * 1997-07-17 1999-01-28 William Harvey Research Limited Use of adenosine tri- or tetra-phosphates and their analogues for the treatment of cerebral infarction
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
KR20010013797A (ko) 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
ID29198A (id) * 1997-08-29 2001-08-09 Univ North Carolina Pemakaian uridin 5'-difosfat dan persamaannya untuk mengobati penyakit paru-paru
AU746582B2 (en) * 1997-10-23 2002-05-02 Southern Research Institute Activating C1-secretion
CA2332540A1 (en) 1998-05-22 1999-12-02 Benjamin R. Yerxa Therapeutic dinucleotide and derivatives
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
EP1143896B1 (de) 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methoden zum befeuchten der nasenschleimhaut
EP2258183A1 (de) 1998-12-22 2010-12-08 The University of North Carolina at Chapel Hill Verbindungen und Verwendungen zur Behandlung von Atemwegeserkrankungen sowie zur Verabreichung von Arzneistoffen für die Atemwege
WO2000050024A2 (en) * 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
KR20020038694A (ko) * 1999-07-19 2002-05-23 프란시스 제이 메이어 소듐 채널 차단제의 콘쥬게이트 및 그 이용방법
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU2001230533A1 (en) * 2000-02-04 2001-08-14 Kissei Pharmaceutical Co. Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
EP2168571B1 (de) 2000-11-30 2018-08-22 Vectura Limited Inhalierbare Arzneizusammensetzung
EP2283818B1 (de) * 2000-11-30 2017-08-02 Vectura Limited Herstellungsverfahren für Partikel zur Verwendung in einer Arrzneizusammensetzung
US20040122223A1 (en) * 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
EP1409503A1 (de) * 2001-07-25 2004-04-21 Celltech R & D Limited Unnatürliche kohlenstoff-verknüpfte nukleotide und dinukleotide
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
JP2007524379A (ja) * 2003-03-31 2007-08-30 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 上皮ナトリウムチャンネル関連障害のＰｈａｒｍｉｃｏ−遺伝子治療
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
AU2007243184A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
WO2008024169A1 (en) * 2006-07-21 2008-02-28 Glsynthesis, Inc. Reactive pyrophosphoric and bisphosphonic acid derivatives and methods of their use
WO2010059215A1 (en) 2008-11-20 2010-05-27 Glsynthesis Inc. Novel antithrombotic diadenosine tetraphosphates and related analogs
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
CN103184067A (zh) * 2012-08-23 2013-07-03 中国海洋石油总公司 一种延长重整生成油分子筛精制催化剂使用寿命的方法
PL2931738T3 (pl) 2012-12-13 2019-07-31 Aduro Biotech, Inc. Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3027227A4 (de) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Stachelkristalle und modulatoren
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3198936A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR102504764B1 (ko) * 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
JP7714247B2 (ja) * 2023-11-10 2025-07-29 祐智 田山 ストーブ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639386A (de) * 1962-10-30
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
AU654979B2 (en) * 1990-10-05 1994-12-01 University Of North Carolina At Chapel Hill, The Method of administering amiloride
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
ES2189874T3 (es) 2003-07-16
EP0831777A1 (de) 1998-04-01
CA2223894C (en) 2007-12-04
DE69625906D1 (de) 2003-02-27
CN1181088C (zh) 2004-12-22
JPH11506790A (ja) 1999-06-15
US20010041682A1 (en) 2001-11-15
US5935555A (en) 1999-08-10
AU6176496A (en) 1996-12-30
US5635160A (en) 1997-06-03
WO1996040059A1 (en) 1996-12-19
EP0831777A4 (de) 1998-05-06
CN1086940C (zh) 2002-07-03
NO975632L (no) 1998-02-03
US6235266B1 (en) 2001-05-22
AU696845B2 (en) 1998-09-17
EP0831777B1 (de) 2003-01-22
KR19990022296A (ko) 1999-03-25
NO975632D0 (no) 1997-12-04
BR9609063A (pt) 1999-01-26
CA2223894A1 (en) 1996-12-19
MX9709637A (es) 1998-07-31
CN1398873A (zh) 2003-02-26
KR100414699B1 (ko) 2004-05-31
DE69625906T2 (de) 2003-11-13
CN1189097A (zh) 1998-07-29

Similar Documents

Publication Publication Date Title
ATE231519T1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
CA2213339A1 (en) Method of treating adenosine depletion
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
AU6286294A (en) Guanidine derivatives useful in therapy
DE69515038D1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
MY115805A (en) Substituted benzyloxycarbonylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
PT100415A (pt) Novas morfolinas de accao farmaceutica, e processo para a sua preparacao
MY118244A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
EP0354568A3 (de) Catechol-Derivate
MY104521A (en) Treatment of depression.
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
ATE31022T1 (de) Verwendung von 4,5'-azo-bis-salicylsaeure zur herstellung eines arzneimittels zur behandlung entzuendlicher darmkrankheiten.
ATE135217T1 (de) Pharmazeutische zusammensetzungen zur aids- behandlung
CA2190952A1 (en) Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
EP0784973A3 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE69630876D1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
ATE210445T1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
DE69509657D1 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831777

Country of ref document: EP